BrightGene Begin Period Cash Flow from 2010 to 2025

688166 Stock   30.14  1.06  3.40%   
BrightGene Bio's Begin Period Cash Flow is increasing over the years with slightly volatile fluctuation. Overall, Begin Period Cash Flow is expected to go to about 764.8 M this year. Begin Period Cash Flow is the amount of cash BrightGene Bio Medical has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. View All Fundamentals
 
Begin Period Cash Flow  
First Reported
2019-12-31
Previous Quarter
971 M
Current Value
948.1 M
Quarterly Volatility
312.4 M
 
Covid
Check BrightGene Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BrightGene Bio's main balance sheet or income statement drivers, such as Tax Provision of 14.9 M, Interest Income of 21.7 M or Interest Expense of 53.6 M, as well as many indicators such as . BrightGene financial statements analysis is a perfect complement when working with BrightGene Bio Valuation or Volatility modules.
  
This module can also supplement various BrightGene Bio Technical models . Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Currently Active Assets on Macroaxis

Other Information on Investing in BrightGene Stock

BrightGene Bio financial ratios help investors to determine whether BrightGene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BrightGene with respect to the benefits of owning BrightGene Bio security.